Nanoprobe Safety and Biocompatibility: What Researchers Need to Know

Applications of Nanoprobes in Targeted Drug Delivery

Passive targeting: Exploits the enhanced permeability and retention (EPR) effect for tumor accumulation (liposomes, polymeric NPs).
Active targeting: Surface ligands (antibodies, peptides, aptamers, small molecules) bind specific biomarkers (e.g., HER2, PSMA) to increase uptake and selectivity.
Stimuli-responsive release: pH, redox, enzyme, temperature, light or magnetic-field triggers permit controlled cargo release at the disease site.

Lipid-based (liposomes, LNPs): High drug loading, approved clinical platforms, tunable circulation via PEGylation.
Polymeric nanoparticles & dendrimers: Controlled release, high functionalization density, size control (useful for BBB penetration).
Inorganic nanoprobes (gold, silica, iron oxide): Stable, easy surface chemistry; enable photothermal, magnetic or imaging-guided delivery.
Quantum dots & fluorescent probes: Theranostic carriers enabling simultaneous imaging and drug delivery.
Exosomes & cell-membrane coated NPs: Biomimetic targeting, improved biocompatibility and circulation.

Imaging + therapy: Nanoprobes combine contrast (optical/NIR, MRI, PET/SPECT) with cargo for real-time tracking and dose optimization.
Photo- and magnetically-triggered therapies: Gold nanorods for photothermal ablation; magnetic NPs for hyperthermia and guided accumulation.
NIR-II probes: Deeper tissue imaging with high SNR, enabling better-guided delivery.

Cancer: Targeted chemotherapy, combination chemo‑photothermal/photodynamic therapy, immunomodulation, and targeted delivery across tumor microenvironment barriers.
Central nervous system: Sub‑15 nm and specially functionalized nanoprobes for blood–brain barrier penetration and delivery of small molecules, siRNA, or peptides.
Gene and oligonucleotide delivery: Polymer and lipid nanoprobes for siRNA/mRNA with endosomal escape strategies.
Immunotherapy & vaccines: Antigen/adjuvant delivery to antigen-presenting cells to boost T-cell responses.
Infectious disease and antimicrobial delivery: Targeted antibiotics or antiviral agents to infection sites, reducing systemic toxicity.